Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 13, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
- Revenues reached a record $1.5 million, up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019 - The number of commercial samples received increased 66% over the third quarter of 2018 and 12% over the second quarter of 2019 - Cost of revenue reduced 23% on a per
Revenues of $6.6 million - a result of decision to offer COVID-19 testing Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to
Revenues for the third quarter of $17.5 million , up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end Robust CNSide™ sequential-quarter volume growth; continued customer base expansion Data generated
CNSide™ study data featured in three poster presentations at leading neuro-oncology annual meeting Participates in UCSF investigator-initiated study to better understand the development and progression of metastatic breast cancer to the central nervous system CNSide orders increased 8% over 2Q 2022
SAN DIEGO --(BUSINESS WIRE)--Mar. 31, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million .
More than 40 million Americans gain access to Biocept's liquid biopsy tests through the FedMed National Provider NetworkBiocept increases coverage to more than 180 million PPO consumers
Increases coverage to approximately 31 million PPO members SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces additional agreements with